Skip to main content

Stacy Mandras, MD

Stacy Mandras, MD

CF-Cardiologist-Transplant

Heart, Lung & Vascular

Stacy Mandras

Overview

Dr. Stacy Mandras is board certified in cardiovascular disease, advanced heart failure and transplant cardiology. She also serves as the Medical Director of Pulmonary Hypertension. She joined AdventHealth in 2020 from New Orleans, where she served as the Director of Pulmonary Hypertension and the Program Director for the Advanced Heart Failure and Transplant Cardiology Fellowship at Ochsner Medical Center. A Phi Beta Kappa honors graduate of the University of Maryland (UM) and the University of Maryland School of Medicine, Dr. Mandras also carried out her internal medicine residency at UM before undertaking consecutive fellowships in cardiovascular medicine and in heart failure and transplant cardiology at Washington University-Barnes-Jewish Hospital in St. Louis, MO. She is proficient in English and Spanish.

Articles

Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 mu g (nine breaths) four times daily

PULMONARY CIRCULATION

2021

Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

2021

Pulmonary hypertension in heart failure

CURRENT OPINION IN CARDIOLOGY

2021

Elusive Diagnosis of Eosinophilic Myocarditis: A Case Series

CURRENT PROBLEMS IN CARDIOLOGY

2021

Ruptured hemorrhagic bulla in a patient with a HeartMate 3 treated with an Amplatzer device

ARCHIVOS DE CARDIOLOGIA DE MEXICO

2021

Rabbit Antithymocyte Globulin Induction in Heart Transplant Recipients at High Risk for Rejection

OCHSNER JOURNAL

2021

Sarcoidosis-Associated Pulmonary Hypertension: An Updated Review and Discussion of the Clinical Conundrum

CURRENT PROBLEMS IN CARDIOLOGY

2021

Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis- Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis

CURRENT PROBLEMS IN CARDIOLOGY

2021

Bariatric Surgery in Patients with Obesity and Ventricular Assist Devices Considered for Heart Transplantation: Systematic Review and Individual Participant Data Meta-analysis

JOURNAL OF CARDIAC FAILURE

2021

Use of TandemHeart as Bridge to Recovery for Antibody-Mediated Rejection in a Heart Transplant Patient.

JACC. Case reports

2020

Education & Training

Education

University of Maryland School of Medicine

Residency

Internal Medicine at University of Maryland

Fellowship

Cardiovascular Disease at Washington University & Barnes Hospital

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT05147805

Insmed Incorporated / “A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension”

Icon for trial | INS 1009-202 Insmed Incorporated / “A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial

'Insmed Incorporated / “A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pul ...

NCT04945460

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

Icon for trial | A011-16 A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ej

This study is currently enrolling.

You are being asked to take part in a research study of an experimental treatment called sotatercept. “Experimental” means that sotatercept is currently being tested and is not approved for sale by any Health Authorities/regula ...

NCT05036135

IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)

Icon for trial | AV-101-002 IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)

This study is currently enrolling.

The purpose of this study is to evaluate what effects, good or bad, the investigational drug AV-101, comparedt to placebo, has on people with pulmonary arterial hypertension (PAH). In order to measure success for this study it ...